scorecardresearch
Zydus Cadila receives USFDA approval to market generic cancer drug in US

Zydus Cadila receives USFDA approval to market generic cancer drug in US

The company has received final approval from the US Food and Drug Administration (USFDA) to market Decitabine for Injection in the strength of 50 mg/vial single-dose vial.

Decitabine is used to treat myelodysplastic syndromes, certain types of blood or bone marrow cancer Decitabine is used to treat myelodysplastic syndromes, certain types of blood or bone marrow cancer

Drug firm Zydus Cadila on Saturday said it has received approval from the US health regulator to market Decitabine injection, used to treat certain types of cancers, in the American market.

The company has received final approval from the US Food and Drug Administration (USFDA) to market Decitabine for Injection in the strength of 50 mg/vial single-dose vial, Zydus Cadila said in a statement.

Decitabine is used to treat myelodysplastic syndromes, certain types of blood or bone marrow cancer. The drug will be manufactured at the group's injectables manufacturing facility, tbe drug maker said.

The Zydus group now has 326 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-04, it added.

Also Read: Govt places purchase order for 1 crore doses of Zydus Cadila's needle-free COVID-19 vaccine

Also Read: Zydus Cadila to supply 1 crore doses of COVID-19 vaccine ZyCoV-D to Indian govt